General Information
Drug ID
DR00153
Drug Name
Fluorouracil
Synonyms
1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5-fluoro-1H-pyrimidine-2,4-dione; 5-fluoropyrimidine-2,4(1H,3H)-dione; 5FU; Adrucil; Adrucil (TN); Allergan Brand of Fluorouracil; Arumel; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Carac; Carac (TN); Carzonal; Cinco FU; Dakota Brand of Fluorouracil; Dakota, Fluorouracile; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Effluderm; Effluderm (free base); Efudex; Efudex (TN); Efudix; Efurix; F 6627; F0151; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroblastin; Fluoroplex; Fluoroplex (TN); Fluorouracil (JP15/USP/INN); Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracil [USAN:INN:BAN:JAN]; Fluorouracil-GRY; Fluorouracile; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo; Fluorouracilo Ferrer Far; Fluorouracilo [INN-Spanish]; Fluorouracilum; Fluorouracilum [INN-Latin]; Fluoruracil; Fluracedyl; Fluracil; Fluracilum; Fluri; Fluril; Fluro Uracil; Fluroblastin; Flurodex; Ftoruracil; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Haemato-fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; IN1335; Inhibits thymilidate synthetase; Kecimeton; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Neofluor; Onkofluor; Onkoworks Brand of Fluorouracil; Phthoruracil; Phtoruracil; Queroplex; Ribofluor; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Ro 2-9757; Ro-2-9757; Roche Brand of Fluorouracil; Tetratogen; Teva Brand of Fluorouracil; Timazin; U 8953; U-8953; URF; Ulup
Drug Type
Small molecular drug
Indication Colon cancer [ICD11: 2B90.Z] Approved [1]
Esophageal cancer [ICD11: 2B70] Approved [1]
Stomach cancer [ICD11: 2B72] Approved [1]
Pancreatic cancer [ICD11: 2C10] Approved [1]
Therapeutic Class
Immunosuppressive Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=3385"></iframe>
3D MOL 2D MOL
Formula
C4H3FN2O2
Canonical SMILES
C1=C(C(=O)NC(=O)N1)F
InChI
InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
InChIKey
GHASVSINZRGABV-UHFFFAOYSA-N
CAS Number
CAS 51-21-8
Pharmaceutical Properties Molecular Weight 130.078 Topological Polar Surface Area 58.2
Heavy Atom Count 9 Rotatable Bond Count 0
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 3
XLogP
-0.9
PubChem CID
3385
PubChem SID
10524722 , 11111190 , 11335229 , 11360468 , 11363735 , 11366297 , 11368859 , 11371368 , 11374392 , 11377021 , 11406045 , 11461440 , 11484027 , 11487892 , 11490250 , 11492372 , 11494655 , 11538022 , 15218968 , 17389875 , 17405099 , 22391543 , 24276773 , 24278439 , 24871165 , 24894963 , 25346604 , 25621761 , 26611750 , 26679238 , 26697058 , 26747342 , 26747343 , 26747344 , 26752979 , 26758708 , 3139714 , 5132902 , 5367838 , 595836 , 603131 , 7847650 , 7891022 , 7978600 , 8139872 , 8149350 , 8152156 , 82653 , 841046 , 9851
ChEBI ID
ChEBI:46345
TTD Drug ID
D05LEO
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
ENT1 Transporter Info Equilibrative nucleoside transporter 1 Substrate [3]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [4]
MRP3 Transporter Info Multidrug resistance-associated protein 3 Substrate [5]
MRP4 Transporter Info Multidrug resistance-associated protein 4 Substrate [5]
MRP5 Transporter Info Multidrug resistance-associated protein 5 Substrate [5]
OAT2 Transporter Info Organic anion transporter 2 Substrate [6]
P-GP Transporter Info P-glycoprotein 1 Substrate [7]
Drug-Transporter Activity Data
Drug-Transporter Activity Data OAT2 Transporter Info Km = 0.0538 microM Oocytes-OAT2 [6]
References
1 Fluorouracil was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
3 Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res. 2007 Jul-Aug;27(4B):2241-9.
4 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
5 ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
6 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
7 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.